<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03292146</url>
  </required_header>
  <id_info>
    <org_study_id>2017P000529</org_study_id>
    <nct_id>NCT03292146</nct_id>
  </id_info>
  <brief_title>Effects of Denosumab on Bone Mineral Density in Women With Anorexia Nervosa: A Pilot Study</brief_title>
  <official_title>Effects of Denosumab on Bone Mineral Density, Markers of Bone Metabolism and Bone Microarchitecture in Women With Anorexia Nervosa: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol is a randomized, double-blind, placebo-controlled clinical trial which aims to
      investigate the effect of denosumab on BMD in women with anorexia nervosa. The investigators
      hypothesize that 6 months of denosumab administration will result in an increase in bone
      mineral density, decrease in markers of bone resorption and improvement in bone
      microarchitecture in osteopenic women with anorexia nervosa compared with placebo.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 25, 2017</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Bone density</measure>
    <time_frame>6 months</time_frame>
    <description>bone density</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Bone Density</condition>
  <condition>Bone Loss</condition>
  <condition>Anorexia Nervosa</condition>
  <condition>Eating Disorder</condition>
  <condition>Atypical Anorexia Nervosa</condition>
  <arm_group>
    <arm_group_label>Active Denosumab 60mg Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One time Denosumab 60mg injection at baseline study visit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One time Placebo injection at baseline study visit</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denosumab 60 MG [Prolia]</intervention_name>
    <description>One time Denosumab 60mg injection for 6 months</description>
    <arm_group_label>Active Denosumab 60mg Injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Injection</intervention_name>
    <description>One time Placebo Injection for 6 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female

          -  Age 20-60 years, skeletally mature with closed epiphyses

          -  Anorexia nervosa or atypical anorexia nervosa defined by DSM-V diagnostic criteria

          -  BMD T-score &lt; -1.0

          -  Normal serum 25-OH vitamin D (&gt;20 ng/mL) and calcium levels

          -  For women of reproductive age, agree to use an effective contraceptive method. Highly
             effective methods of birth control include:

               -  Combined (estrogen and progestogen) hormonal methods (pills, vaginal ring, or
                  skin patch)

               -  Intrauterine device (IUD)

               -  Intrauterine hormonal-releasing system (IUS)

               -  Surgery to tie both fallopian tubes (bilateral tubal ligation/occlusion)

               -  Your male partner has had a vasectomy and testing shows there is no sperm in the
                  semen

          -  Dental check up within the past year

        Exclusion Criteria:

          -  Any disease known to affect bone, including untreated thyroid dysfunction, Cushing's
             or renal failure

          -  Any medication known to affect bone metabolism within 3 months of the study, excluding
             oral contraceptives or other forms of estrogen administration. Bisphosphonates must
             have been discontinued for at least one year before participation

          -  Immunodeficiency or taking immunosuppressive therapy

          -  Serum potassium &lt;3.0 meq/L

          -  Serum ALT &gt;3 times upper limit of normal

          -  eGFR of less than 30 ml/min

          -  Hypocalcemia

          -  Diabetes mellitus

          -  Active substance abuse, including alcohol

          -  History of malignancy

          -  Paget disease of bone

          -  Osteomalacia

          -  Osteonecrosis of the jaw (ONJ) or risk factor for ONJ, such as invasive dental
             procedures (eg, tooth extraction, dental implants, oral surgery in the past 6 months),
             poor oral hygiene, periodontal and/or pre-existing dental disease, and current use of
             corticosteroids

          -  Planned invasive dental procedure over the next 6 months

          -  Known sensitivity to any of the products or components to be administered during
             dosing or known sensitivity to mammalian cell derived drug products

          -  Sensitivity to calcium or vitamin D supplements

          -  Pregnant, planning to become pregnant with 7 months after the end of treatment and/or
             breastfeeding
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen K Miller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen K Miller, MD</last_name>
    <phone>617-726-3870</phone>
    <email>KKMILLER@partners.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Erinne Meenaghan, NP</last_name>
    <phone>617-724-7393</phone>
    <email>EMEENAGHAN@partners.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Miller, MD</last_name>
      <phone>617-726-3870</phone>
      <email>kkmiller@mgh.harvard.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2017</study_first_submitted>
  <study_first_submitted_qc>September 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2017</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Karen Klahr Miller, MD</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Feeding and Eating Disorders</mesh_term>
    <mesh_term>Anorexia</mesh_term>
    <mesh_term>Anorexia Nervosa</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

